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Serum deprivation of human marrow stromal cells (hMSCs) selects for a
subpopulation of early progenitor cells with enhanced expression
of OCT-4 and other embryonic genes
Radhika R. Pochampally, Jason R. Smith, Joni Ylostalo, and Darwin J. Prockop
Recently there has been interest in devel-
oping cell and gene therapies with adult
stem cells from human bone marrow re-
ferred to as mesenchymal stem cells or
marrow stromal cells (hMSCs). We incu-
bated early-passage hMSCs in serum-
free medium without cytokines or other
supplements for 2 to 4 weeks. Surpris-
ingly, a subpopulation of the cells sur-
vived serum deprivation and then began
to proliferate in serum-containing me-
dium. The cells selected by serum depri-
vation had longer telomeres than control
cells. Also, the patterns of gene expres-
sion revealed by reverse transcriptase–
polymerase chain reaction (RT-PCR) as-
says and microarray data indicated that
the cells selected by serum deprivation
were a subpopulation of very early pro-
genitor cells with enhanced expression of
octomer-binding transcription factor 4
(OCT-4) and several other genes charac-
teristically expressed in embryonic cells.
(Blood. 2004;103:1647-1652)
© 2004 by TheAmerican Society of Hematology
Introduction
Human mesenchymal stem cells or marrow stromal cells (hMSCs)
can differentiate into osteoblasts, chondrocytes, adipocytes, myo-
cytes, and other cell types.1-9 They are readily isolated from bone
marrow by their adherence to tissue culture plastic and can be
expanded extensively in medium containing high concentrations of
fetal calf serum (FCS). The cells are readily cloned as single-cell–
derived colonies, but both the colonies and the cells within a colony
are heterogeneous in morphology, rates of proliferation, and
efﬁcacy with which they differentiate.3,10,11 Two morphologically
distinct cell phenotypes are seen in early-passage, low-density
cultures: small, spindle-shaped cells that are rapidly self renewing
(RS cells) and large, ﬂat cells that replicate slowly and appear more
mature.3,10,12 The proportion of RS cells remains high for several
passages if the cultures are maintained at low density, but the larger
cells predominate in later passages and the cells cease proliferation
at about the Hayﬂick limit of 50 population doublings.9,10,12,13,
Several investigators10,13-15 identiﬁed distinctive surface epitopes
on hMSCs but none of the epitopes have been shown to distinguish
early progenitors from more mature cells in cultures of hMSCs.
Marrow cells that may or may not be related to hMSCs were
recently isolated by ﬁrst selecting Lin and glycophorin marrow
cells and then culturing the cells on ﬁbronectin-coated plated cells
in medium containing 2% FCS and a series of growth factors.16,17
After about 25 population doublings, cultures of multipotent adult
precursor cells (MAPCs) were obtained that expressed telomerase,
were multipotential for differentiation, and continued to expand
for well over 50 population doublings. Recently, we found that a
subpopulation of hMSCs with distinctive features can be selected
from early-passage cultures of hMSCs by incubation of the
cells for 2 to 4 weeks without serum, growth factors, or other
supplements.
Materials and methods
Human MSCs were prepared as described previously.10,12 In brief, nucle-
ated cells were isolated with a density gradient (Ficoll-Paque; Pharmacia,
Uppsala, Sweden) from 2 mL human bone marrow aspirated from the iliac
crests of healthy volunteers under a protocol approved by the Institutional
Review Board of Tulane University Health Sciences Center. All the
nucleated cells (30 to 70 million) were plated in a 145-cm2 dish in 20 mL
complete culture medium: –modiﬁed minimum essential media (MEM;
GIBCO BRL, Carlsbad, CA); 17% fetal bovine serum ([FBS] lot-selected
for rapid growth of MSCs; Atlanta Biologicals, Norcross, GA); 100
units/mL penicillin; 100 g/mL streptomycin; and 2 mM L-glutamine
(GIBCO BRL). After 24 hours at 37°C in 5% CO2, nonadherent cells were
discarded and the adherent cells were incubated in fresh medium for 4 days.
The cells were lifted with 0.25% trypsin and 1 mM EDTA (ethylenedi-
aminetetraacetic acid) for 5 minutes at 37°C and replated at 50 cells/cm2 in
an interconnecting system of culture ﬂasks (6320 cm2; Cell Factory; Nunc,
Wiesbaden, Germany). After 7 to 9 days, the cells were lifted with
trypsin/EDTA, suspended at about 106 cells/mL in 5% dimethyl sulfoxide
(DMSO) and 30% FCS in MEM and frozen in 1-mL aliquots in liquid
nitrogen as passage 1 cells. The vials of passage 1 cells were thawed, plated
in a 60-cm2 dish, incubated for 4 days, and lifted with trypsin/EDTA to
recover viable cells. The cells were then plated in complete medium at
50 to 500 cells/cm2, incubated for 4 to 7 days, and lifted with trypsin/EDTA
to recover passage 2 cells. Later-passage cells were obtained by replating
the cells at 50 to 500 cells/cm2, incubating them for 4 to 7 days, and
recovering the cells with trypsin/EDTA.
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later-passage cells were plated at 50 to 500 cells/cm2 in 15-cm diameter
plates. One set of plates was washed with phosphate-buffered saline (PBS)
and incubated with MEM without serum or growth factors to prepare SD
cells. The second set was incubated with complete culture medium with
FCSasaparallelcontrolset.Themediumwasreplacedevery4daysfor2to
4 weeks.After serum deprivation, both control and SD cells were recovered
by lifting with trypsin/EDTA and replated with complete culture medium
with 17% FCS. Both controls and SD cultures were expanded in complete
culture medium containing FCS.
Telomere length assay
In assays of telomere lengths, the day-0 sample was prepared by plating
passage 2 hMSCs at 100 cells/cm2 in a 15-cm diameter dish and incubating
in complete medium for 5 days.The SD sample was prepared by incubation
of the day-0 sample in medium without FCS for 3 weeks, then replating all
the surviving cells in a 15-cm diameter dish, and incubation in complete
medium for 5 days. The control sample was prepared by incubating the
day-0 sample in complete medium for 3 weeks, then replating at 100
cells/cm2, and incubation in complete medium for 5 days. Genomic DNA
was isolated from 1  106 cells (MagNA Pure LC DNA Isolation Kit I;
Roche Molecular Biochemicals, Indianapolis, IN) and telomere length was
assayed with a commercial kit (TeloTagg; Roche Molecular Biochemicals).
In brief, 10 g genomic DNAwas digested with RsaI and Southern blotted
into nylon membrane. Telomere lengths were determined using chemilumi-
nescent assay to detect digoxigenin (DIG)–labeled probe.
Western blot analysis
Cells were prepared as for the assays of telomere length and lysed in buffer
(Lysis Buffer; Roche Molecular Biochemicals) supplemented with protease
inhibitor cocktail (Sigma Biochemicals, St Louis, MO) and protein
concentration was determined (Micro BCA Kit; Pierce Biotechnology,
Rockford, IL). The cell lysate (50 to 100 g of protein) was fractionated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE;
Novex 12% gels; Invitrogen, Carlsbad, CA). The sample was transferred to
a ﬁlter (Immobilon P; Millipore, Bedford, MA) by electro-blotting (Immu-
noblotting Apparatus; Invitrogen). The ﬁlter was blocked for 30 minutes
with PBS containing 5% nonfat dry milk and 0.1% Tween 20 and then
incubated for one hour with the primary antibody. For detection of p21WAF1,
the ﬁlter was incubated with 1:500 dilution of anti-p21 antibody (Pharmin-
gen, San Diego, CA). The p53 was detected by incubating with a 1:500
monoclonal antibody (DO-1; Pharmingen). The ﬁlter was washed 4 times
for 15 minutes each with PBS containing 0.1% Tween 20. Bound primary
antibody was detected by incubating for 1 hour with horseradish peroxidase
goat antimouse immunoglobulin G (IgG; Pharmingen) diluted 1:10 000 in
PBS containing 5% nonfat dry milk. The ﬁlter was washed with PBS
containing 0.1%Tween 20 and developed using a chemiluminescence assay
(West-Femto Detection Kit; Pierce Biotechnology).
RT-PCR analysis
RNA was isolated from 0.5  106 cells (RNeasy RNA Isolation Kit;
Qiagen, Valencia, CA) and 50 ng total RNA was used to perform one-step
reverse transcriptase–polymerase chain reaction (RT-PCR; Titan One Step
RT-PCR Kit; Roche Biochemical). Five microliters of the product was
loaded for agarose gel electrophoresis. For semiquantitative RT-PCR
analysis, 100, 20, and 4 ng of total RNA was used to perform one-step
RT-PCR. The following primer sets were used: catalytic subunit of
telomere replicating telomerase (hTERT):5 -cgctggtggcccagtgcctg and
5-ctcgcacccggggctggcag; OCT-4:5 -cgctccggcccacaaatctc and 5-ccgcac-
gacaaccgcaccat;ornithinedecarboxylase(ODC)antizyme:5-ccgcacgacaac-
cgcaccat and 5-cgctccggcccacaaatctc; activating transcription factor 5
(ATF-5):5 -aaggagctggaacagatggaagac and 5-ttgtaaacctcgatgagcaggtcc;
ﬁbroblast growth factor-2 (FGF2):5 -gtgtgctaaccgttacctggctat and 5-
aggtaagcttcactgggtaacagc; FGF2 receptor (FGF2R):5 -tgtgctaaccgttacctg-
gctatg and 5-aggtaagcttcactgggtaacagc; glutathione-S–transferase (GST):
5-tgggaagaacaagatcacccagag and 5-gttgtccaggtagctcttccaagt; keratin-
associated protein 1 (KAP1):5 -acccaaccttcagatcaactcctg and 5-ccggtt-
gagaagctaggaaatcca; lysyl oxidase (LOX):5 -ttacccagccgaccaagatattcc and
5-tcataacagccaggactcaatccc; sine oculis homeobox homolog-2 (SIX2):
5-actgagtcttgaaccacagaaggg and 5-acagaaggagagaatgaacggtgg; ho-
meobox C6 (HOXC6):5 -tcaattccaccgcctatgatccag and 5-aatcctgagcgatt-
gaggtctgtg; and -actin: 5-tcatgaagtgtgacgttgacatccgt and 5-cttagaagca-
tttgcggtgcacgatg.
Clonogenicity, growth curve, and differentiation assays
For the clonogenicity assay, cells were plated at 1 cell/well into a 96-well
plate using an automated instrument (Clonecyte Accessory and FACSvan-
tage; BD Biosciences, San Jose, CA). The cells were incubated with
complete culture medium for 10 days, stained with Crystal Violet, and
colonies with diameters of 2 mm or greater were counted. For the
differentiation assay, the cells were plated at 1 cell/well in a 96-well plate
and incubated in complete culture medium for 9 days and medium was
changed to either osteogenic medium (108 M dexamethasone/0.2 mM
ascorbic acid/10 mM -glycerolphosphate; Sigma) or adipogenic medium
(0.5 M hydrocortisone/0.5 mM isobutylmethylxanthine/60 M indometh-
acin). The incubation was continued for 3 weeks with a change of medium
every 4 days. The cells were ﬁxed with 10% formalin and stained with
Alizarin Red (Sigma) or Oil Red O (Fisher Scientiﬁc, Hampton, NH). For
chondrocyte differentiation, a pellet culture system18 was used. Approxi-
mately 200 000 MSCs were placed in a 15-mLpolypropylene tube (Falcon,
Heidelberg, Germany) and centrifuged to pellet. The pellet was cultured at
37°C with 5% CO2 in 500 L chondrogenic media that contained 500
ng/mL bone morphogenetic protein-6 (BMP-6; R&D Systems, Minneapo-
lis, MN) in addition to high-glucose Dulbecco modiﬁed Eagle medium
(DMEM) supplemented with 10 ng/mL transforming growth factor-3
(TGF-3), 107 M dexamethasone, 50 g/mL ascorbate-2-phosphate, 40
g/mL proline, 100 g/mL pyruvate, and 50 mg/mL ITS Premix (6.25
g/mL insulin, 6.25 g/mL transferrin, 6.25 ng/mL selenious acid, 1.25
mg/mL bovine serum albumin [BSA], and 5.35 mg/mL linoleic acid;
Becton Dickinson, San Jose, CA). The medium was replaced every 3 to 4
days for 21 days. For immunostaining, parafﬁn-embedded sections were
deparafﬁnized using xylene and rehydrated though graded alcohols. The
pellet was pretreated with 25 mg/mL hyaluronidase (Sigma) in PBS for 30
minutes at 37°C for optimal antigen retrieval.After washing in PBS 3 times
at room temperature, nonspeciﬁc staining was blocked with PBS containing
10% normal goat serum for 1 hour at room temperature. Rabbit antibody
against type II collagen (1:500; Cosmo Bio, Tokyo, Japan) was placed on
section for 72 hours at 4°C. After washing with PBS, the sections were
incubated with biotinylated goat antirabbit (1:500; Vector Laboratories,
Braintree, MA) for 1 hour at room temperature, washed, and then incubated
with streptavidin-conjugated Texas Red (1:400; Vector Laboratories) for 1
hour at room temperature. The slides were washed in PBS, dried, and
coverslipped with antifade mounting medium containing DAPI (4,6
diamidino-2-phenylindole; Vectashield; Vector Laboratories). For growth
curve assay, 105 cells were plated into 3 wells of a 6-well plate. The cells
were trypsinized and counted after 5 days of incubation. The data presented
here are a mean of 2 donor samples.
Microarray analysis
Total RNA was extracted (RNeasy Kit; Qiagen) from 1  106 cells of 5
samples from each of 2 donors as described in Figure 4A. The RNA
expression was assayed with a chip containing oligonucleotide probes for
about 22 000 human genes (HG-U133A array; Affymetrix, Santa Clara,
CA). For the initial ﬁltering for reproducibility of the data, the Microarray
Suite 5.0 program (Affymetrix) was used to obtain signal intensities. The
data were then ﬁltered in the following steps: (1) genes that were not
consistently scored as absent or present in the 3wkS (cells incubated with
serum for 3 weeks) and 3wkSD (cells incubated without serum for 3 weeks)
samples from both donors (Figure 4A) were eliminated; (2) genes scored as
absent in all 4 samples were eliminated; (3) steps 1 and 2 were combined to
reduce the number of genes to about 8000; (4) genes in the 4 samples that
did not show signiﬁcant change from day 0 (Figure 4A) were eliminated;
(5) genes that did not show consistent scores of increase or decrease in the 4
1648 POCHAMPALLY et al BLOOD, 1 MARCH 2004 VOLUME 103, NUMBER 5
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From samples were eliminated; (6) steps 4 and 5 were combined to reduce the
number of genes to 915; and (7) steps 5 and 6 were repeated for the 4
samples of 5dSDS (3wkSD samples incubated for 5 days in medium
containing 17% FCS) and 5dSS (3wkS samples incubated for 5 days in
medium containing 17% FCS) and redundancies were eliminated to reduce
the number of genes to 842. The hierarchical cluster analysis was carried
out on the 842 genes with the dChip 1.3 program.19 Adjacent genes were
merged if the cluster of merged genes maintained the same pattern of
expression.
Results
The experiments were carried out with frozen vials of passage 2
hMSCs that were previously shown to expand rapidly in cul-
tures.12,13The vials were thawed and viable cells were recovered by
incubating them on the plates for 2 days in complete medium
containing FCS. The adherent viable cells were lifted with trypsin/
EDTA, plated at 100 cells/cm2, and incubated in complete medium
containing FCS for 5 days so that the cultures expanded into the log
phase of growth and about half the cells consisted of RS cells.10,12
The medium was then replaced with the same medium devoid of
serum, growth factors, or other supplements, and the incubation
continued for 2 to 4 weeks. Initially, many of the cells in the
serum-free medium appeared apoptotic and necrotic (Figure 1).
Control cultures incubated in medium containing FCS became
conﬂuent. The SD cells were lifted with trypsin/EDTA, plated at
100 cells/cm2, and incubated in medium containing FCS. After 5
days, the morphology of the SD cells changed from large,
apparently senescent cells to the spindle-shaped cells characteristic
of early-passage hMSCs (Figure 1).
The replated SD cells (not shown) displayed a lag period of 4 to
5 days similar to the lag period seen when standard cultures of
hMSCs are replated.10,12 Thereafter, the SD cells grew rapidly with
a doubling time of about 24 hours for 4 to 5 days and until the
cultures approached conﬂuence. The SD cells were more clono-
genic than parallel samples incubated for 4 weeks at the same
densities in medium containing FCS (Figure 2A). The colonies
formed were smaller than colonies formed by controls (not shown),
but the SD cells retained their potential to differentiate into
adipocytes and mineralizing cells (Figure 2C-D). The cells also
differentiated into chondrocytes that expressed type II collagen
(Figure 2E). However, the micropellets formed stained only weakly
for proteoglycans, indicating that the differentiation into chondro-
cytes was not robust.18 Although SD cells continued to propagate
longer than the control cells, they underwent senescence after
passage 10 (Figure 2B), suggesting that they are not immortal.
MSCs from 34 donors were incubated without serum and SD cells
were obtained from 28 donors. However, the yields varied more
than 10-fold, an observation consistent with previous observations
indicating that preparations of MSCs varied in their content of early
progenitors.9,10 Only 4% to 7% of SD cells and control cultures of
MSCs were positive in assays for stromal antigen 1 (Stro-1; not
shown) that was used to characterized some MSCs.14
In assays of SD cells prepared from 15 different donors of bone
marrow aspirates, the average telomere lengths were consistently
longer than in the same cultures before serum deprivation (Figure
3A).Also, the average telomere lengths in the SD cells were longer
than in control cells from the same hMSC preparations that were
incubated in parallel in serum-containing medium. Assays for
telomerase activity gave low and variable values for both SD cells
and controls (not shown). RT-PCR (not shown) and Western blot
Figure 2. Clonogenicity, expansion, and differentiation of SD cells. (A) Percent
of cells that gave colonies after plating single cells into separate wells (1-3) of a
96-well microtiter plate. (B) Cumulative population doubling in medium containing
17% FCS as a function of passage number (p4 to p10). (C) Differentiation of SD cells
into adipocytes (original magniﬁcation,  10). Cells stained with Oil Red O. (D) Differ-
entiation of SD cells into mineralizing cells (original magniﬁcation,  10). Cells
stained with Alizarin Red. (E) Differentiation of SD cells into chondrocytes (original
magniﬁcation,  40).
Figure 1. Phase contrast micrographs of hMSCs during and after selection for
SD cells. (Top row) Before recovery of SD cells. (Bottom row) After recovery of SD
cells. Passage 2 hMSCs were incubated in complete medium containing 17% FCS
for 28 days with a change of medium every 4 days to obtain control cells. Parallel
hMSC cultures were incubated under the same conditions in medium without serum
to obtain SD cells. The SD cells were then recovered by incubation in medium with
17% FCS for 1 to 5 days. Original magniﬁcation,  10.
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genes not usually expressed in transformed cells.20,21 Soft agar
assays to test for the loss of contact inhibition did not show any
colonies with either control or SD cells, and no tumor growths were
apparent 5 weeks after immunodeﬁcient mice were subcutaneously
injected with 2 million SD cells per mouse (n  10). Therefore,
there was no evidence that the cells were transformed.
On the basis of these observations, we tested the hypothesis that
the SD cells expressed a proﬁle of genes more characteristic of
early progenitors than the other cells in cultures of hMSCs. Cells
from 2 different donors were assayed under 5 different conditions:
(1) initial plating of passage 2 hMSCs at low density (100
cells/cm2) and incubation for 5 days (day-0 cells in Figure 4) so that
the cultures contained about equal proportions of RS cells and more
mature cells10,12; (2) incubation of the day-0 samples in serum-free
medium for 3 weeks (3wkSD cells in Figure 4A); (3) incubation of
parallel day-0 samples in serum-containing complete medium for 3
weeks (3wkS); (4) replating and incubation of 3wkSD samples in
serum-containing medium for 5 days (5dSDS) so that the cells
regained their original spindle-shaped morphology (Figure 1); (5)
replating and incubation of the 3wkS samples in serum-containing
medium for 5 days (5dSS).
RT-PCR assays (Figure 4A) indicated that mRNA levels were
higher in SD cells than in controls for Oct-4, hTERT, and ODC
antizyme, 3 genes characteristically expressed in embryonic
cells.22-25The same RNAsamples were assayed by microarrays and
the data were analyzed by hierarchical clustering of the genes by
their patterns of expression.26 In brief (Figure 5), the data from a
chip containing about 22 000 genes were ﬁrst ﬁltered, and differen-
tially expressed genes and 842 ﬁltered genes were assigned to
hierarchical clusters with the dChip 1.3 program19 (Figure 6).
The 24 clusters were further ﬁltered to identify (1) clusters in
which genes were down-regulated in response to serum deprivation
and remained down-regulated when the cells were returned to
medium containing FCS (down/down pattern); and (2) clusters in
which genes were up-regulated and remained up-regulated (up/up
pattern). Six down/down clusters (arbitrarily numbered 11, 12, 14,
17, 19, and 22), and 3 up/up clusters (numbers 3, 7, and 9) were
identiﬁed. The functional annotations assigned to 5 of the 6
down/down clusters by the dChip program19 (Figure 6) included
genes encoding membrane fractions and membrane-associated
receptors or transporters. Two of 6 down/down clusters (clusters 11
and 14) also included genes for intermediary metabolism. One
down/down cluster (cluster 14) contained a gene for an apoptosis
inhibitor. The 3 up/up clusters included genes involved in develop-
ment, morphogenesis, and organogenesis (cluster 3); genes in-
volved in regulation of cell cycle, genes for an endothelial growth
factor–like (EGF–like) calcium binding protein, RNA polymerase
II transcription factor, and cell motility (cluster 7); and genes for a
transcription corepressor, nitrogen metabolism, and homeobox
protein C6 (cluster 9).
In the next step of analysis of the microarray data (Figure 5), we
examined in greater detail 5 individual genes from the down/down
clusters that are expressed in differentiated cells and 5 genes from
the up/up clusters that are expressed in uncommitted cells. The 5
down/down genes (Figure 7) included a tumor suppressor gene also
referred to as LOX because it encodes an enzyme that is required
for the extracellular cross-linking of collagen and elastin; GST that
is involved in the blood barrier in brain and testes; neural stem
cell–derived neuronal survival protein (SDNSF); FGF2; and
KAP1. The up/up genes (Figure 7) included ATF-5 that binds to the
cyclic adenosine monophosphate (cAMP) response elements in
many promoters; angiopoietin-1 (ANP-1) that promotes sprouting
of endothelial cells; FGF2R; SIX2; and HOXC6 that belongs to the
family of homeobox D4 genes involved in early development.
RT-PCR assays (Figure 8) conﬁrmed the expression patterns of
the 10 genes in the 2 donors used for microarray analysis. RT-PCR
assays on samples from 3 additional donors demonstrated that 2 of
Figure 3. Telomere length assay and Western blots.
(A) Telomere length assay. Passage 2 cells were plated
at 100 cells/cm2 for 5 days and then incubated in medium
with and without 17% FCS for 28 days as in Figure 1.
Day-0 cells were assayed before initial plating. The
control and SD cells were allowed to recover in medium
with FCS for 5 days. (B) Western blot for p53 and p21
with hMSCs from 3 different donors. The hMSCs were
incubated with and without serum as for panel A. A
human ﬁbrosarcoma cell line, HT1080, was used as a
positive control.
Figure 4. RNA and RT-PCR. (A) Schemes for the
preparation of cells for microarray and RT-PCR analyses.
Day 0 indicates initial samples of passage 2 hMSCs;
3wkSD and 3wkS, cells incubated without or with serum
for 3 weeks; and 5dSDSS and 5dS, 3wkSD and 3wkS
samples incubated for 5 days in medium containing 17%
FCS. (B) RT-PCR analyses of RNA obtained from the
samples described in panelAshowing enhanced expres-
sion of genes that are expressed in very early progenitor
cells.
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HOXC6, KAP1, and LOX (not shown).Asemiquantitative RT-PCR
assay on HOXC6 and LOX (Figure 8C) conﬁrmed the difference in
expression pattern of the genes (Figure 8C).
Discussion
We also analyzed the data for expression of genes that were
recently identiﬁed as signature genes for murine stem cells.27,28
About half of the genes with human homologs were present in the
ﬁltered data from one or more of the samples of SD cells and
control MSCs but there were no large and persistent differences in
expression that distinguished the SD cells. In addition, we exam-
ined the unﬁltered data from the experiments for expression of the
polycromb group gene Bmi-1 that is essential for the self renewal
of hematopoietic stem cells.29,30 The gene was expressed in all 5
sets of samples and there were no signiﬁcant changes in the level
of expression.
The results demonstrate that subjecting early-passage hMSCs to
serum deprivation for 2 to 4 weeks selects for a distinct subpopula-
tion of cells. The SD cells are remarkable in that they survive
complete serum deprivation for prolonged periods of time, have
Figure 5. Scheme for analysis of data from microarrays.
Figure 6. Hierarchical cluster analyses of 842 genes expressed in SD and
control cells. The data on samples are presented in the order (left to right) day 0,
3wkSD, 5dSDS, 3wkS,  5dSS (see Figure 4A).
Figure 7. Genes showing prominent down/down and up/up patterns. LOX
indicates lysyl oxidase (accession no. NM_002317); GST, glutathione-S–transferase
(AL527430);SDNSF,neuralstemcell–derivedneuronalsurvivalprotein(BE_880828);
FGF2, ﬁbroblast growth factor-2 (M27968); KAP-1, keratin associated protein-1
(NM_030967); ATF-5, activating transcription factor 5 (NM_012068); ANP-1, angio-
poietin-1 (U83508); FGFR2, ﬁbroblast growth factor receptor-2 (NM_022969); SIX2,
sineoculishomeoboxhomolog-2(AF3332197);HOXC6,homeoboxC6(NM_004503).
The black line and diamonds indicate SD cells; red line and squares, control cells; 0,
21, and 5 samples prepared as in Figure 4A.
Figure 8. RT-PCR analyses. (A-B) RT-PCR analyses to conﬁrm the expression
patterns of the genes shown in Figure 6. (C) Semiquantitative RT-PCR analysis of
HOXC6 and LOX of 3wkS and 3wkSD samples.
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primarily in early progenitor cells. At the same time, the SD cells
retained most of the characteristics of hMSCs in that they generated
single-cell–derived colonies and they differentiated into osteo-
blasts, chondrocytes, and adipocytes. SD cells were obtained from
75% of early-passage hMSCs obtained from more than 30 separate
donors of marrow aspirates. The yield of SD cells decreased
markedly with passage number so that they could not be isolated
from hMSCs preparations after 3 passages (not shown). Therefore,
SD cells were probably not present in signiﬁcant numbers in the
hMSC preparations used in most previous experiments. Compared
with the hierarchy of a hematopoietic system,31 RS cells that were
previously identiﬁed as a rapidly self-renewing subpopulation in
hMSC cultures10 are probably comparable to transitory amplifying
cells. SD cells are more slowly replicating earlier progenitors and
therefore more closely resemble hematopoietic stem cells or
embryonic stem cells.
Acknowledgments
The authors wish to thank Mr Alan Tucker for ﬂow cytometer
support and Dr Leena Ala-Kokko for critical reading of the
manuscript.
References
1. FriedensteinAJ. Bone marrow osteogenic stem
cells: in vitro cultivation and transplantation in dif-
fusion chambers. Cell Tissue Kinet. 1987;20:263-
272.
2. Owen ME, FriedensteinAJ. Stromal stem cells:
marrow-derived osteogenic precursors. In: Cell
and Molecular Biology of Vertebrate Hard Tis-
sues, Ciba Foundation Symposium. Chichester,
United Kingdom: John Wiley & Sons; 1988:42-60.
3. Mets T, Verdonk G. In vitro aging of human bone
marrow-derived stromal cells. MechAgeing Dev.
1981;16:81-89.
4. PiersmaAH, Brockbank KGM, Ploemacher RE,
van Vliet E, Brakel-van Peer KMJ, Visser
PJ. Characterization of ﬁbroblastic stromal cells
from murine bone marrow. Exp Hematol. 1985;
13:237-243.
5. Castro-Malaspina H, Gay RE, Resnick G, et al.
Characterization of human bone marrow ﬁbro-
blast colony-forming cells (CFU-F) and their prog-
eny. Blood. 1980;56:289-301.
6. CaplanAI. Mesenchymal stem cells. J Orthop
Res. 1991;9:641-650.
7. Prockop DJ. Marrow stromal cells as stem cells
for nonhematopoietic tissues. Science. 1997;276:
71-74.
8. Pittinger MF, MackayAM, Beck SC, et al. Multilin-
eage potential of adult human mesenchymal
stem cells. Science. 1999;284:143-147.
9. DiGirolamo CM, Stokes D, Colter D, Phinney DG,
Class R, Prockop DJ. Propagation and senes-
cence of human marrow stromal cells in culture: a
simple colony-forming assay identiﬁes samples
with the greatest potential to propagate and differ-
entiate. Br J Haematol. 1999;107:275-281.
10. Colter DC, Sekiya I, Prockop DJ. Identiﬁcation of
a sub-population of rapidly self-renewing and
multipotential adult stem cells in colonies of hu-
man marrow stromal cells. Proc NatlAcad Sci
U SA. 2001;98:8741-8745.
11. Bruder SP, Jaiswal N, Haynesworth SE. Growth
kinetics, self-renewal, and the osteogenic poten-
tial of puriﬁed human mesenchymal stem cells
during extensive subcultivation and following
cryopreservation. J Cell Biochem. 1997;64:278-
294.
12. Sekiya I, Larson BL, Smith JR, Pochampally R,
Cui J-G, Prockop DJ. Expansion of human adult
stem cells from bone marrow stroma: conditions
that maximize the yield of early progenitors and
for evaluating their quality. Stem Cells. 2002;20:
430-441.
13. Colter DC, Class R, DiGirolamo CM, Prockop DJ.
Rapid expansion of recycling stem cells in cul-
tures of plastic-adherent cells from human bone
marrow. Proc NatlAcad Sci U SA. 2000;96:7294-
7299.
14. Gronthos S, Simmons PJ, Graves SE, Robey
PG. Integrin-mediated interactions between hu-
man bone marrow stromal precursor cells and the
extracellular matrix. Bone. 2001;28:174-181.
15. Barry FP, Boynton RE, Haynesworth S, Murphy
JM, Zaia J. The monoclonal antibody SH-2,
raised against human mesenchymal stem cells,
recognizes an epitope on endoglin (CD105). Bio-
chem Biophys Res Commun. 1999;265:134-139.
16. Barry F, Boynton R, Murphy M, Haynesworth S,
Zaia J. The SH-3 and SH-4 antibodies recognize
distinct epitopes on CD73 from human mesen-
chymal stem cells. Biochem Biophys Res Com-
mun. 2001;289:519-524.
17. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluri-
potency of mesenchymal stem cells derived from
adult marrow. Nature. 2002;418:41-49.
18. Sekiya I, Vuoristo J, Larson BL, Prockop DJ. In
vitro cartilage formation by human adult stem
cells from bone marrow stroma deﬁnes the se-
quence of cellular and molecular events during
chondrogenesis. Proc NatlAcad Sci U SA. 2002;
99:4397-4402.
19. Wong C and Li WH. Hierarchical clustering.Avail-
able at: http://biosun1.harvard.edu/complab/
dchip/clustering.htm.AccessedApril 2003.
20. Reyes M, Lund T, Lenvik T,Aguiar D, Koodie L,
Verfaillie CM. Puriﬁcation and ex vivo expansion
of postnatal human marrow mesodermal progeni-
tor cells. Blood. 2001;98:2615-2625.
21. LevineAJ. p53, the cellular gatekeeper for growth
and division. Cell. 1997;88:323-331.
22. LundbergAS, Hahn WC, Gupta P, Weinberg RA.
Genes involved in senescence and immortaliza-
tion. Curr Opin Cell Biol. 2000;12:705-709.
23. Pesce M, Scholer HR. Oct-4: gatekeeper in the
beginnings of mammalian development. Stem
Cells. 2001;19:271-278.
24. Blackburn EH. Switching and signaling at the
telomere. Cell. 2001;106:661-673.
25. Iwata S, Sato Y,Asada M, et al.Anti-tumor activity
of antizyme which targets the ornithine decarbox-
ylase (ODC) required for cell growth and transfor-
mation. Oncogene. 1999;18:165-172.
26. Li C, Wong WH. Model-based analysis of oligonu-
cleotide arrays: expression index computation
and outlier detection. Proc NatlAcad Sci U SA.
2001;98:31-36.
27. Ivanova NB, Dimos JT, Schaniel C, Hackney JA,
Moore KA, Lemischka IR.Astem cell molecular
signature. Science. 2002;298:601-604.
28. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulli-
gan RC, Melton DA. “Stemness”: transcriptional
proﬁling of embryonic and adult stem cells.
Science. 2002;298:597-600.
29. Park IK, Qian D, Kiel M, et al. Bmi-1 is required
for maintenance of adult self-renewing haemato-
poietic stem cells. Nature. 2003;423:302-305.
30. Lessard J, Sauvageau G. Bmi-1 determines the
proliferative capacity of normal and leukaemic
stem cells. Nature. 2003;423:255-260.
31. WagersAJ, Christensen JL, Weissman IL. Cell
fate determination from stem cells. Gene Ther.
2002;9:606-612.
1652 POCHAMPALLY et al BLOOD, 1 MARCH 2004 VOLUME 103, NUMBER 5
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From 